Migraine Trial, Recruiting (NCT06735833)

Migraine Trial, Recruiting NCT06735833 Sponsor: Cerenovus, Part of DePuy Synthes Products, Inc. Condition: Migraine

Printed from Voxsanity (voxsanity.com.au) — NCT06735833 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Migraine

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You are between 18 and 65 years old at the time of signing up for the study
Your chronic migraine condition started at age 64 or younger
You were first diagnosed with migraines before the age of 50
You have been diagnosed with migraines that have not responded well to standard treatments (sometimes called "refractory migraine")
You currently have a diagnosis of chronic migraine

Who may not be able to join:

You have had other types of headache disorders (apart from headaches caused by overusing pain medication) in the last 2 years
You have been diagnosed with a type of migraine that causes temporary paralysis or weakness (hemiplegic migraine), or a migraine that has caused a stroke
You currently use opioid painkillers, cannabis, medical marijuana, or similar substances on a regular basis
You are pregnant, breastfeeding, or are a woman of childbearing age
You are currently taking part in another clinical trial involving a drug, device, or other experimental treatment that could affect the results of this study (note: being part of an observational or natural history study without any treatment may still be allowed, and the study sponsor must give approval)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 23 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06735833

Sponsor: Cerenovus, Part of DePuy Synthes Products, Inc.

Phase: Not Applicable

Status: Recruiting

Condition: Migraine

More information: https://clinicaltrials.gov/study/NCT06735833

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You are between 18 and 65 years old at the time of signing up for the study
Your chronic migraine condition started at age 64 or younger
You were first diagnosed with migraines before the age of 50
You have been diagnosed with migraines that have not responded well to standard treatments (sometimes called "refractory migraine")
You currently have a diagnosis of chronic migraine

Who may not be able to join:

You have had other types of headache disorders (apart from headaches caused by overusing pain medication) in the last 2 years
You have been diagnosed with a type of migraine that causes temporary paralysis or weakness (hemiplegic migraine), or a migraine that has caused a stroke
You currently use opioid painkillers, cannabis, medical marijuana, or similar substances on a regular basis
You are pregnant, breastfeeding, or are a woman of childbearing age
You are currently taking part in another clinical trial involving a drug, device, or other experimental treatment that could affect the results of this study (note: being part of an observational or natural history study without any treatment may still be allowed, and the study sponsor must give approval)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 23 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Cerenovus, Part of DePuy Synthes Products, Inc.

Registry

ClinicalTrials.gov

Start date

23 April 2025

Est. completion

25 December 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change from baseline, in number of migraine days

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov